Indirect comparative efficacy and safety of tirzepatide versus oral semaglutide for the treatment of overweight and obesity
Ciudin A, Johansson E, Zimner-Rapuch S, et al.
Diabetes Obes Metab. Pub. online 28 Apr 2026.
Leggi
Time delays between fingerstick glucose measurements and correctional insulin administration in the hospital: do they really matter?
Flint KL, Fahey A, Longo R, et al.
Diabetologia. Pub. online 22 Apr 2026.
Leggi
SGLT2 inhibitor use and disparities in all-cause mortality in type 2 diabetes: insights from a multi-ethnic population
Chepulis L, Gan H, Simmons D, et al.
Diabetologia. Pub. online 24 Apr 2026.
Leggi
Perspectives on human adipose tissue: from cellular mechanisms to clinical complications
Rydén M
Diabetologia. Pub. online 24 Apr 2026.
Leggi
Dose–response associations of intermittent lifestyle physical activity micropatterns and incident type 2 diabetes
Chong KH, Ahmadi MN, Biswas RK, et al.
Diabetes Care. Pub. online 28 Apr 2026.
Leggi
Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes results from the VESALIUS-CV trial
Marston NA, Bohula EA, Bhatia AK, et al.
JAMA. Pub. online 28 Mar 2026.
Leggi
Adipose as a driver, not a bystander: a modern synthesis of obesity‐related erectile dysfunction
Sailis AB, Mat Noh MA
Diabetes Obes Metab. Pub. online 27 Apr 2026.
Leggi
FDA – Drug Safety-related Labeling Changes (SrLC)
20 aprile 2026
Leggi
EMA – New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome
24 aprile 2026
Leggi
Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments
Liu C, Mujahid O, Beneyto A, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi